NASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis $11.35 +0.12 (+1.07%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$11.25 -0.10 (-0.87%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cullinan Therapeutics Stock (NASDAQ:CGEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cullinan Therapeutics alerts:Sign Up Key Stats Today's Range$11.15▼$11.6850-Day Range$10.80▼$22.3352-Week Range$7.72▼$23.19Volume983,252 shsAverage Volume830,414 shsMarket Capitalization$730.43 millionP/E RatioN/ADividend YieldN/APrice Target$34.14Consensus RatingModerate Buy Company Overview Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells. Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases. These candidates remain investigational and are not approved treatments. Founded as Cullinan Oncology, the company adopted the name Cullinan Therapeutics in 2024 to reflect its expanded focus beyond oncology. It is headquartered in Cambridge, Massachusetts, and is led by President and Chief Executive Officer Nadim Ahmed.AI Generated. May Contain Errors. Read More Cullinan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreCGEM MarketRank™: 3.305562844395 of 5 starsCullinan Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 358th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCullinan Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCullinan Therapeutics has a consensus price target of $34.14, representing about 200.8% upside from its current price of $11.35.Amount of Analyst CoverageCullinan Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cullinan Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cullinan Therapeutics are expected to grow in the coming year, from ($3.06) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Therapeutics has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.48% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 13.33, which indicates bearish sentiment.Change versus previous monthShort interest in Cullinan Therapeutics has recently increased by 3.78%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.79 News SentimentCullinan Therapeutics has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Cullinan Therapeutics this week, compared to 5 articles on an average week.Search Interest5 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows11 people have added Cullinan Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $829,800.00 in company stock.Percentage Held by Insiders8.60% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGEM Stock News HeadlinesCullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsNovember 10 at 7:00 AM | globenewswire.comCullinan Therapeutics to Participate in Upcoming Investor ConferencesNovember 9 at 10:00 AM | globenewswire.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th. | Behind the Markets (Ad)Cullinan Reports Phase 1b/2a Study Data For Velinotamig In SLE Patients; Stock UpNovember 9 at 8:30 AM | rttnews.comVelinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR ...November 8, 2026 | marketscreener.comMVelinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026November 8, 2026 | globenewswire.comCullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 4,000 Shares of Company StockNovember 7, 2026 | insidertrades.com3 Growth Stocks Under $20 With Hard Catalyst Dates AheadAlmonty Industries, Kopin and Cullinan Therapeutics trade under $20, and each faces a near-term catalyst: China tungsten curbs, CES and a February FDA decision.October 28, 2026 | marketbeat.comSee More Headlines CGEM Stock Analysis - Frequently Asked Questions How have CGEM shares performed this year? Cullinan Therapeutics' stock was trading at $10.35 at the beginning of 2026. Since then, CGEM stock has increased by 9.7% and is now trading at $11.35. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) announced its earnings results on Tuesday, November, 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.84) by $0.10. When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $232 million in an initial public offering on Friday, January 8th 2021. The company issued 11,900,000 shares at a price of $19.00-$20.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Therapeutics' major shareholders? Top institutional investors of Cullinan Therapeutics include Fisher Asset Management LLC (1.24%), Ellsworth Advisors LLC (0.12%), Russell Investments Group Ltd. (0.05%) and AlphaCentric Advisors LLC (0.03%). Insiders that own company stock include Lynx1 Capital Management Lp, Nadim Ahmed, Corrine Savill, Jeffrey Alan Jones, Jennifer Michaelson, Jacquelyn L Sumer, Mary Kay Fenton and Jeffrey Trigilio. View institutional ownership trends. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cullinan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Iovance Biotherapeutics (IOVA), Broadcom (AVGO), Palantir Technologies (PLTR), IonQ (IONQ), NIKE (NKE), Fate Therapeutics (FATE) and Kopin (KOPN). Company Calendar Last Earnings11/10/2026Today11/12/2026UBS Global Biopharma Conference 202611/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, CGEM's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CGEM CIK1789972 Webwww.cullinantherapeutics.com Phone617-410-4650FaxN/AEmployees109Year Founded2016Price Target and Rating Average Price Target for Cullinan Therapeutics$34.14 High Price Target$44.00 Low Price Target$26.00 Potential Upside/Downside+200.8%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$219.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-55.66% Return on Assets-50.23% Debt Debt-to-Equity RatioN/A Current Ratio8.42 Quick Ratio8.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book1.64Miscellaneous Outstanding Shares64,355,000Free Float58,820,000Market Cap$730.43 million OptionableOptionable Beta-0.03 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CGEM) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredThis 10.3% war bond closed once. It's finally open again.Todd Phillips has spent 30 years studying safe-money income. His test for real retirement income: can it promi...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
